Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Adult women (≥ 18 years of age) with metastatic or locally advanced breast cancer not amenable to curative treatment by surgery or radiotherapy.
Histological or cytological confirmation of estrogen-receptor positive (ER+) breast cancer
Postmenopausal women.
Disease refractory to non steroidal aromatase inhibitors (NSAI),
Radiological or clinical evidence of recurrence or progression on or after the last systemic therapy prior to randomization.
Patients must have at least one lesion that can be accurately measured or bone lesions in the absence of measurable disease as defined above.
You may not be if
HER2-overexpressing patients
Patients with only non-measurable lesions other than bone metastasis (e.g. pleural effusion, ascites etc.).
Patients who received more than one chemotherapy line for Advanced Breast Cancer.
Previous treatment with exemestane or mTOR inhibitors.
Known hypersensitivity to mTOR inhibitors, e.g. sirolimus (rapamycin).
Radiotherapy within four weeks prior to randomization
Currently receiving hormone replacement therapy,
Clareo Health | Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
